|
|
 |
|
References |  |
|
|
- Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes—TAP report no. 3. Arch Ophthalmol. 2002;120:1443-1454.
- Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
- Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report no. 2. Arch Ophthalmol. 2001;119:198-207.
- Vingerling JR, Klaver CC, Hoffman A, de Jong PTVM. Epidemiology of age-related maculopathy. Epidemiol Rev. 1995;17:347-360.
- Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
- Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102:1640-1642.
|
|
